Roth Capital Lowers Accuray's Q3 Earnings Estimates

Accuray Incorporated (NASDAQ:ARAY - Free Report) has seen a reduction in its Q3 2025 earnings per share (EPS) estimates, according to stock analysts at Roth Capital. In a research note issued to investors on Wednesday, February 12th, Roth Capital's analyst J. Wittes adjusted the forecast, now predicting that the medical equipment company will report an EPS of ($0.05) for the quarter. This is a downward revision from the previous estimate of $0.01. In comparison, the consensus estimate for Accuray's full-year earnings is currently $0.01 per share. Additionally, Roth Capital has put forward expectations for Accuray's Q4 2025 earnings, estimating an EPS of $0.08.

Accuray last reported its earnings on February 5th, 2025, revealing an EPS of $0.02 for the quarter, exceeding analysts' consensus predictions of ($0.01) by $0.03. Despite this positive surprise, Accuray has faced challenges with a negative net margin of 0.96% and a negative return on equity of 9.75%.

In related news, StockNews.com has recently upgraded Accuray’s rating from “hold” to “buy” in a report made available on Monday.

Accuray Stock Performance

As of Friday, Accuray shares opened at $2.28, reflecting a 2.2% rise in trading. The company's financial metrics indicate significant leverage, with a debt-to-equity ratio of 3.51. It also has a current ratio of 1.62 and a quick ratio of 0.87. With a market capitalization of approximately $234.45 million, Accuray exhibits a PE ratio of -45.60 and a beta of 1.51, showing its volatility relative to the market. The stock has experienced fluctuations, hitting a 1-year low of $1.40 and a high of $2.95 within the past year. The fifty-day simple moving average stands at $2.13, while the 200-day simple moving average is at $1.98.

Institutional Involvement

Recent activity among hedge funds and institutional investors indicates an increased interest in Accuray. Notable transactions include AQR Capital Management LLC acquiring a new position in the company valued at $30,000 during the second quarter, and US Bancorp DE raising its stake by an impressive 1,087.7% in the third quarter to hold 17,816 shares valued at $32,000. Other institutional investors, such as Caprock Group LLC, Intech Investment Management LLC, and Prudential Financial Inc., also purchased new stakes in the company, adding to the growing institutional ownership which currently sits at 64.08%.

About Accuray Incorporated

Accuray Incorporated specializes in the design, development, manufacturing, and sales of radiosurgery and radiation therapy systems aimed at tumor treatment. Its offerings include the CyberKnife platform, which is a robotic stereotactic radiosurgery system. This technology is employed for treating both primary and metastatic tumors outside the brain, including those near the spine and in other organs like the breast, kidney, liver, lung, pancreas, and prostate.

Earnings, Stocks, Accuray